the National Colorectal Cancer Cohort (NCRCC) Study: National Colorectal Cancer Research Consortium
The National Colorectal Cancer Cohort Study-Precision Medical Research in Colorectal Cancer
1 other identifier
observational
55,000
1 country
5
Brief Summary
NCRCC study is a national prospective cohort study including colorectal cancer screening population and stage Ⅰ-Ⅳ colorectal cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
August 26, 2019
CompletedFirst Posted
Study publicly available on registry
August 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2035
August 30, 2019
August 1, 2019
22.9 years
August 26, 2019
August 28, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
colorectal cancer incidence
up to 15 years
Disease-free and overall survival
up to 10 years
Recurrence/metastasis
up to 5 years
Adenoma or advanced adenoma incidence
up to 1 year
Secondary Outcomes (2)
Prevalence of treatment-related toxicities characterized by the Common Toxicity Criteria for Adverse Events (CTCAE)
up to 5 years
Second primary cancer incidence
up to 15 years
Eligibility Criteria
NCRCC study consists of two subcohorts (CRC Screening Cohort and Colorectal Cancer Patient Cohort). CRC Screening Cohort is a population-bsaed study. All aged 40-74 years old individuals without prior colorectal cancer or bowel resection are recruited. All consecutive patients who were newly diagnosed with primary invasive or metastatic colorectal cancer are eligible for Colorectal Cancer Patient Cohort.
You may qualify if:
- Men and women
- Mentally/physically able to consent and participate
- Subjects aged ≥18 years old (Colorectal Cancer Patient Cohort, CRCPC), age 40-74 years (CRC Screening Cohort, CRCSC)
- Newly-diagnosed colon and rectal cancer for stages Ⅰ-Ⅳ (CRCPC)
You may not qualify if:
- A history of colorectal cancer or bowel resection
- Non-Chinese speaking
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ding Ke-Fenglead
- Cancer Institute and Hospital, Chinese Academy of Medical Sciencescollaborator
- West China Hospitalcollaborator
- Sun Yat-sen Universitycollaborator
- Shanghai Zhongshan Hospitalcollaborator
- Peking University People's Hospitalcollaborator
- Peking University Cancer Hospital & Institutecollaborator
- Fujian Cancer Hospitalcollaborator
- Hubei Cancer Hospitalcollaborator
- The First Affiliated Hospital with Nanjing Medical Universitycollaborator
- Shanxi Province Cancer Hospitalcollaborator
- Changhai Hospitalcollaborator
- Zhejiang Cancer Hospitalcollaborator
- Third Affiliated Hospital of Third Military Medical Universitycollaborator
- Air Force Military Medical University, Chinacollaborator
- Sixth Affiliated Hospital, Sun Yat-sen Universitycollaborator
Study Sites (5)
Second Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, Zhejiang, 310999, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
West China Hospital
Chengdu, China
Sun Yat-sen University
Guangzhou, China
Shanghai Zhongshan Hospital
Shanghai, China
Related Publications (2)
Huang F, Xiao T, Li K, Wei R, Mei S, Zhao W, Wei F, He M, Zheng Z, Liu Q. Benefit of oxaliplatin-based chemotherapy or capecitabine monotherapy in older patients with stage III and high-risk stage II colon cancer: Data from the National Colorectal Cancer Cohort study in China. Chin Med J (Engl). 2025 Nov 10. doi: 10.1097/CM9.0000000000003813. Online ahead of print.
PMID: 41213862DERIVEDHuang F, Jiang S, Wei R, Xiao T, Wei F, Zheng Z, Liu Q. Association of resection margin distance with anastomotic recurrence in stage I-III colon cancer: data from the National Colorectal Cancer Cohort (NCRCC) study in China. Int J Colorectal Dis. 2024 Jul 12;39(1):105. doi: 10.1007/s00384-024-04684-x.
PMID: 38995409DERIVED
Biospecimen
Formalin fixed and paraffin embedded (FFPE) and fresh frozen tissue (multiple sources/locations) from the tumor, blood, urine, feces
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 26, 2019
First Posted
August 30, 2019
Study Start
January 1, 2013
Primary Completion (Estimated)
December 1, 2035
Study Completion (Estimated)
December 1, 2035
Last Updated
August 30, 2019
Record last verified: 2019-08